PV Bulletin

MHRA Clarifies Regulatory Pathways for Microbiome-Based Medicinal Products

The MHRA's recent position paper outlines the regulatory framework for microbiome-based medicinal products (MBMPs) in the UK, confirming their classification under existing medicinal regulation.

Primary source: Guidance and regulation

PV Impact Brief

Urgency: HighConfidence: high

What changed

The MHRA has confirmed the regulatory classification of microbiome-based medicinal products under the existing framework and provided specific guidance on safety assessments, product characterization, and suggested early engagement with their Innovation Office.

Why it matters

This guidance allows developers of microbiome therapies to understand the expectations for compliance including safety assessments for AMR risks and supports effective planning in navigating the licensing process, which can significantly impact development timelines and regulatory success.

Action needed

Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Literature SurveillanceCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice / Position Paper
Policy status
Final
Publication date
2026-08-18
Policy change
The MHRA has issued a position paper clarifying the regulatory and licensing pathways for microbiome-based medicinal products (MBMPs) in the UK. The document confirms that MBMPs fall under the Human Medicines Regulations 2012 and may be regulated as biologicals or advanced therapy medicinal products (ATMPs). It provides guidance on product characterization, safety assessment (including AMR risks), and the generation of clinical evidence required for licensing.

Key changes

Clarifies that MBMPs are regulated as biological medicinal products or ATMPs under existing frameworks. Sets specific expectations for developers regarding product characterization, manufacturing consistency, and safety assessments for antimicrobial resistance (AMR) risk. Reaffirms that faecal microbiota transplantation (FMT) remains under the 'specials' or clinical trial routes for specific indications.

Affected workflows

Literature SurveillanceCountry Compliance

Responsible groups

Regulatory AffairsClinical SafetyPV Operations

PV impact

Developers of microbiome therapies must align their safety assessment protocols with the MHRA's expectations for antimicrobial resistance risk and batch-to-batch variability. Early engagement with the MHRA Innovation Office or Scientific Advice is recommended to de-risk development and agree on proportionate safety monitoring and clinical evidence strategies.

View regulator source

Source document details

Exact policy details

UK licensing route for microbiome-based medicines
Microbiome-based medicinal products fall within the scope of the existing UK medicines regulatory framework.
Applies to: Applicable to developers of microbiome-based medicinal products in the UK seeking licensing pathways.
The position paper clarifying how microbiome-based medicines can be made available. · p. 1 · High · Source
MHRA's position on microbiome-based medicinal products
No microbiome-based medicinal product currently holds a UK marketing authorisation.
Applies to: Relevant for developers and stakeholders in the microbiome product sector.
No MBMP currently holds a UK marketing authorisation, as detailed in the position paper. · p. 1 · High · Source
Regulatory framework for microbiome products
Microbiome-based medicinal products may be regulated as biological medicinal products or as advanced therapy medicinal products.
Applies to: Developers of microbiome-based medicinal products should assess their product's characteristics.
They may be regulated as biological medicinal products, or in some cases may meet the criteria for advanced therapy medicinal products (ATMPs). · p. 1 · High · Source
Scientific and regulatory steps for developers
Key steps include product characterisation, manufacturing consistency, and safety assessment.
Applies to: For developers of microbiome-based medicinal products seeking to comply with MHRA standards.
Some of the key scientific and regulatory steps developers should consider are product characterisation and safety assessment. · p. 1 · High · Source
Encouragement for early engagement
MHRA encourages early engagement for clarifying the regulatory framework.
Applies to: Developers of microbiome-based medicinal products.
The MHRA is encouraging developers to make use of its Innovation Office and Scientific Advice services at an early stage. · p. 1 · High · Source
Faecal microbiota transplantation (FMT) arrangements
FMT is used for specific indications and supplied through clinical trials or unlicensed medicine arrangements.
Applies to: Applicable to clinicians using FMT in patient care.
FMT is currently used for specific indications and remains under the direct responsibility of the prescribing clinician. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 18, 2026

Full briefing

Practical implication

Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a position paper providing clarity on the regulatory and licensing pathways for microbiome-based medicinal products (MBMPs) in the UK. It specifies that MBMPs are regulated under the Human Medicines Regulations 2012 and may be classified as biological medicinal products or advanced therapy medicinal products (ATMPs). The document emphasizes essential aspects such as product characterization, safety assessments including antimicrobial resistance (AMR) risks, and the generation of clinical evidence necessary for gaining licenses. Furthermore, it stresses the importance of early engagement with the MHRA for developers.

What changed: The MHRA has confirmed the regulatory classification of microbiome-based medicinal products under the existing framework and provided specific guidance on safety assessments, product characterization, and suggested early engagement with their Innovation Office.

Why it matters: This guidance allows developers of microbiome therapies to understand the expectations for compliance including safety assessments for AMR risks and supports effective planning in navigating the licensing process, which can significantly impact development timelines and regulatory success.

Practical implication: Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Medicines and Healthcare products Regulatory Agency (MHRA)#final#policy-change#Guidance#firecrawl-policy-agent#Microbiome Products#Regulatory Guidance#Notice / Position Paper

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Atellica CH Revised C-Reactive Protein (RCRP) Safety Information - Siemens Healthcare Diagnostics

Urgency: High

Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward